Quantification of Corticosteroid-Induced Skin Vasoconstriction: Visual Ranking, Chromameter Measurement or Digital Imaging AnalysisSmith E.W.a · Haigh J.M.b · Surber C.c
aCollege of Pharmacy, Ohio Northern University Ada, Ohio, USA; bFaculty of Pharmacy, Rhodes University, Grahamstown, South Africa, and cInstitute of Hospital Pharmacy, Department of Dermatology and Department of Pharmacy, University of Basel, Switzerland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Topical corticosteroid formulations have been evaluated by visual grading protocols for many years. Toward a more objective methodology, several instrumental methods have been evaluated for applicability in quantifying the vasoconstriction side-effect that follows corticosteroid application to the skin. Although the chromameter has been adopted by regulatory bodies throughout the world as the current standard for topical bioequivalence determinations, there is considerable criticism of this instrument from several quarters. A preliminary comparison reported here indicates that digital image analysis provides statistically significant results that are similar to those obtained by visual assessment techniques, and shows considerably greater precision than that obtained by the chromameter. Continued evaluation of objective assessment techniques, such as digital imaging, and continued modernisation of regulatory bioequivalence requirements will assist in protecting patients and optimising clinical results.
© 2002 S. Karger AG, Basel
- Schwarb FP, Imanidis G, Smith EW, Haigh JM, Surber C: Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin. Pharm Res 1999;16:909–915.
Surber C, Smith EW: The vehicle: The pharmaceutical carrier of dermatological agents; in Gabard B, Elsner P, Surber C, Treffel P (eds): Dermatopharmacology of Topical Preparations. A product-development oriented approach. Berlin, Springer, 1999, pp 5–21.
Haigh JM, Smith EW, Meyer E, Fassihi R: Influence of the oil phase dispersion in a cream base on the in vivo release of betamethasone 17-valerate. STP Pharma Sci 1992;2:259–264.
Bircher AJ, Hauri U, Niederer M, Hohl C, Surber C: Stealth triamcinolone acetonide in a phytocosmetic cream. Br J Dermatol, in press.
Wells GC: The effect of hydrocortisone on standardized skin-surface trauma. Br J Dermatol 1957;69:11–18.
- Cornell RC, Stoughton RB: Correlation of the vasoconstrictor assay and clinical activity in psoriasis. Arch Dermatol 1985;121:63–67.
McKenzie AW, Stoughton RB: Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962;86:608–610.
- Haigh JM, Kanfer I: Assessment of topical corticosteroid preparations: The human skin blanching assay. Int J Pharm 1984;19:245–262.
- Smith EW, Meyer E, Haigh JM: Blanching activities of betamethasone 17-valerate formulations: The effect of the dosage form on topical drug availability. Arzneimittelforschung 1990;40:618–621.
Haigh JM, Meyer E, Smith EW, Kanfer I: The human skin blanching assay for in vivo topical corticosteroid assessment. 1. Reproducibility of the assay. Int J Pharm 1997;152:179–183.
Haigh JM, Smith EW, Maibach HI: New developments in the methodology available for the assessment of topical corticosteroid-induced skin blanching; in Bronaugh RL, Maibach HI (eds): Percutaneous Absorption. New York, Marcel Dekker, 1998, vol 3, pp 487–498.
Haigh JM, Meyer E, Smith EW, Kanfer I: The human skin blanching assay for in vivo topical corticosteroid assessment. 2. Subject- and observer-dependent variation in blanching responses. Int J Pharm 1997;152:185–192.
- Shah VP, Peck CC, Skelly JP: ‘Vasoconstriction’-skin blanching assay – a critique. Arch Dermatol 1989;125:1558–1561.
Adams WP, Singh GJP: Guidance: Topical dermatologic corticosteroids: In vivo bioequivalence. Division of Bioequivalence, Office of Generic Drugs, Food and Drug Administration, Rockville, 1995.
Pershing LK: Assessment of topical corticosteroid-induced skin blanching response using the visual McKenzie-Stoughton and colorimetric methods. Drug Info J 1995;29:923–934.
Smith EW, Meyer E, Haigh JM: Accuracy and reproducibility of the multiple-reading skin blanching assay; in Maibach HI, Surber C (eds): Topical Corticosteroids. Basel, Karger, 1992, pp 65–73.
- Meyer E, Magnus AD, Haigh JM, Kanfer I: Comparison of the blanching activities of Dermovate, Betnovate and Eumovate creams and ointments. Int J Pharm 1988;41:63–66.
- Meyer E, Smith EW, Haigh JM: Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanching. Br J Dermatol 1992;127:379–381.
- Stoughton RB: Are genetic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 1987;123:1312–1314.
- Demana PH, Smith EW, Walker RB, Haigh JM, Kanfer I: Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing. Pharm Res 1997;14:303–307.
- Smith EW, Walker RB, Haigh JM, Kanfer I: Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioequivalence testing – addendum. Pharm Res 1998;15:4–7.
- Schwarb FP, Smith EW, Haigh JM, Surber C: Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: Comparison of visual and chromameter data. Eur J Pharm Biopharm 1999;47:261–267.
Smith EW, Haigh JM, Walker RB: Analysis of chromameter results obtained from corticosteroid-induced skin blanching. 1. Manipulation of data. Pharm Res 1998;15:280–285.
Surber C, Smith EW, Schwarb FP, Maibach HI: Drug concentration in the skin; in Bronaugh RL, Maibach HI (eds): Percutaneous Absorption. Drugs – Cosmetics – Mechanisms – Methodology. New York, Marcel Dekker, 1999, ed 3, pp 347–374.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.